OncLive SOSS

Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Dr. Burtness on Findings of KEYNOTE-048 in Head and Neck Cancer

October 22nd 2018, 10:53pm

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses findings from the KEYNOTE-048 in head and neck squamous cell carcinoma (HNSCC).

Dr. Parker on the Role of Radiotherapy in Newly Diagnosed Prostate Cancer

October 22nd 2018, 10:52pm

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the role of radiotherapy in newly diagnosed prostate cancer.

Cisplatin Remains Standard for Low-Risk HPV+ Oropharyngeal Cancer

October 22nd 2018, 9:28pm

Cisplatin plus radiotherapy results in better overall survival and the same rate of all-grade toxicity compared with cetuximab plus radiotherapy in patients with HPV-positive oropharyngeal cancer.

Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma

October 22nd 2018, 8:58pm

Long-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treated with adjuvant dabrafenib plus trametinib.

Trifluridine/Tipiracil Extends Survival in Heavily Pretreated Gastric/GEJ Cancer

October 22nd 2018, 8:11pm

Trifluridine/tipiracil reduces the risk of death by about one-third compared with placebo in patients with heavily pretreated gastric or gastroesophageal junction cancer.

Pembrolizumab Improves OS, but Not PFS and ORR in Frontline HNSCC

October 22nd 2018, 7:58pm

Frontline pembrolizumab monotherapy showed an improvement in overall survival and duration of response versus standard therapy in patients with PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma; however, there was not a similar improvement in progression-free survival or overall response rate with the PD-1 inhibitor.

Atezolizumab Plus Bevacizumab Shows Durable Activity in Advanced HCC

October 22nd 2018, 5:33pm

The combination of the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab showed promising and durable antitumor activity in a phase Ib study of patients with advanced hepatocellular carcinoma.

Rucaparib Responses Reached in Nearly Half of Men With BRCA+ mCRPC

October 22nd 2018, 5:08pm

Preliminary data from the ongoing phase II TRITON2 trial demonstrated a 44% confirmed objective response rate by investigator assessment among evaluable men with BRCA1/2-mutated metastatic castration-resistant prostate cancer who were treated with the PARP inhibitor rucaparib.

Higher Dose of Ipilimumab Added to Nivolumab Effective in Bladder Cancer

October 22nd 2018, 2:56am

Extended follow-up data from the CheckMate-032 study shows a trend toward higher overall response and longer progression-free survival with the regimen of nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg in patients with platinum-pretreated metastatic urothelial carcinoma.

Entrectinib Active Across Multiple Tumor Types

October 22nd 2018, 1:44am

More than half of patients with advanced solid tumors associated with NTRK gene fusions responded to treatment with the small-molecule inhibitor entrectinib, an integrated analysis of 3 clinical trials showed.

Olaparib Substantially Improves PFS as Frontline Maintenance in Ovarian Cancer

October 22nd 2018, 1:14am

The PARP inhibitor olaparib significantly improved progression-free survival as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase III SOLO-1 trial.

Larotrectinib Demonstrates High Response Rate, Durability in NTRK+ Cancers

October 21st 2018, 11:01pm

Patients with advanced cancers associated with NTRK gene fusions had an 80% objective response rate with the TRK inhibitor larotrectinib, pooled results from three small trials showed.

Tepotinib Plus Gefitinib Improves PFS in MET+ EGFR-Mutant NSCLC

October 21st 2018, 10:58pm

The combination of tepotinib plus gefitinib improved progression-free survival and overall response versus chemotherapy in patients with MET mutated EGFR-positive non–small cell lung cancer resistant to prior EGFR TKI therapy.

Dr. Andre on the Impact of the SOLAR-1 Findings in Breast Cancer

October 21st 2018, 10:21pm

Fabrice André, MD, PhD, professor, Department of Medical Oncology, Institut Gustave Roussy, discusses the impact of the SOLAR-1 findings in breast cancer at the 2018 ESMO Congress.

Engineered Anti-MAGE-A T-Cells Show Early Promise

October 21st 2018, 10:20pm

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.

Radiotherapy Raised to New Standard in Newly Diagnosed Prostate Cancer With Low Metastatic Burden

October 21st 2018, 7:50pm

When added to standard of care therapy, radiotherapy to the prostate improves overall survival in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden.

Dr. Arkenau on Survival Data With TAS-102 in Gastric Cancer

October 21st 2018, 7:32pm

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Cannon Research Institute UK, discusses survival data with TAS-102 (trifluridine/tipiracil; Lonsurf) in gastric cancer at the 2018 ESMO Congress.

Avelumab/Axitinib Nearly Doubles PFS, ORR in Frontline RCC

October 21st 2018, 6:47pm

The combination of avelumab and axitinib doubled objective response rates and significantly improved progression-free survival compared with sunitinib in patients with treatment-naïve advanced renal cell carcinoma regardless of PD-L1 expression.

Niraparib Effective in Later Lines of Therapy for Relapsed Ovarian Cancer

October 21st 2018, 1:38am

The PARP inhibitor niraparib has shown durable clinical activity in later lines of therapy in patients with relapsed ovarian cancer who have BRCA mutations, according to a posthoc analysis of the phase II QUADRA study.

Alpelisib Combo Nearly Doubles PFS in PIK3CA-Mutant Breast Cancer

October 21st 2018, 1:26am

The addition of the PI3K inhibitor alpelisib to fulvestrant nearly doubled median progression-free survival compared with the endocrine therapy alone in patients with HR-positive/HER2-negative advanced breast cancer who have a PIK3CA mutation.